Clinically, FLT3 overexpression has been associated with adverse prognosis, particularly in MLL-AF4+ B-ALL, where it serves as an independent predictor of poor survival and treatment failure [34,35]. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.